Evolving Best Practices for Working with Authors – Authorship and Beyond


24th October, 2017
Time: 16:00 - 17:00

Location: Webinar
Timezone: (GMT) Western Europe Time, London, Lisbon, Casablanca

Developing scientific publications and manuscripts is a complex and time-intensive process. Each publication often involves managing multiple authors and KOLs through numerous review rounds, while gathering actionable and meaningful input and meeting stringent publication deadlines.

Join us to learn good publication practices that will help to streamline your interactions with scientific authors, while enhancing the quality, efficiency and effectiveness of your industry sponsored research projects.

Key Insights:

We will review best practices for ensuring that authors meet ICMJE guidelines in manuscript development and submissions, and offer suggestions and solutions to help you meet the high demand for rapid publication. Learn more about:

  • Best practices for working with scientific authors who write their own manuscripts from sponsored trials
  • What to do when an internal investigator/author has left the company
  • How to limit the number of authors listed on a publication, with examples of how this can work in everyday practice
  • Criteria to determine appropriate authorship and how to credit each author
  • Strategies to manage author expenses and other payments, including travel and reimbursements, and when it is appropriate to pay an author
  • Easy to use technology solutions that provide compliant and efficient means to support your strategic and tactical publication management processes. 

Overview

While there are many definitions of value, Michael Porter’s “health outcomes achieved per dollar spent” resonates well. To apply this requires recognition of what stakeholder spends the dollar, what they get for their investment, over what time period that investment results in a return, or health-related value, and how and who defines that value. Considered broadly, this relates to how various healthcare resources are utilized as well as how they are allocated across the health care system. Once launched, an ideal new intervention should lead to more efficient resource utilization for all stakeholders.

Conceptually, an economic investment in a new drug or device designed to deliver a high quality health outcome results in a meaningful and reproducible improvement in clinical or humanistic outcomes for patients. An improved health outcome for the patient defines the fundamental value for the new intervention. It is reasonable to expect that an economic investment in a high quality health outcome should offer an offsetting value, or reason why patients and care providers should have access to that new entity. The reality, however, is that stakeholders’ values often are not universally aligned and one or more of them may perceive that their opportunity to obtain value from the new product is somehow compromised. In the United States health care system, this often relates to an imbalance in the perception of the timeline between purchasing the investment and realizing the offsetting value.

We will discuss value return periods, how various stakeholders perceive them, and how this relationship must be mapped out prior to determining what value proposition may be best aligned throughout the health care system and how that understanding will inform the strategic process for design and implementation of a robust evidence development plan. 


Presented by:

Surendra Sharma, MD

Medical Communications Leader, Spark Therapeutics

Surendra Sharma has over 10 years of pharmaceutical and biotechnology industry experience and has held multiple cross-functional leadership roles in medical affairs and content / publication review. He has expertise developing scientific platforms for successful launch, including global and local KOL platforms, MSL training platforms, and development of medical information and medical publications. In August 2017 he joined Spark Therapeutics as Communications Leader for ophthalmology and haemophilia. Previously, he led Alcon’s global medical submission teams for the launch of CyPass® Micro-Stent, a micro invasive glaucoma surgical device. 


Janet Galliera

Executive Director Business Development, PubsHub, an ICON plc company

Janet has 18 years of experience in medical communications. She currently manages the PubsHub technology suite of web-based solutions, including tools to easily manage and collaborate on scientific publication development, planning and management. Previously, she was the Director of Client Services and Project Management at Complete Healthcare Communications Group (acquired by ICON). Janet is an active member of the International Society for Medical Publication Professionals (ISMPP) and was chair of the IMSPP workshops from 2008 to 2012.


Target Audience

This webinar is intended for publication professionals working in:

  • Medical or clinical publications
  • Medical or scientific communications
  • Medical writing
  • Medical and clinical affairs

Register today to learn good publication practices that will enhance the quality, efficiency and effectiveness of your industry sponsored research.